X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SLN360 (zerlasiran) is a phase 2 investigational siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovascular disease affecting up to 20% of the world’s population.
Lead Product(s): Zerlasiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
Through collaboration, Silence and AstraZeneca will initiate clinical trial studies by using Silence’s proprietary mRNAi GOLD platform to develop siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases.
Lead Product(s): mRNAi-based Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $570.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration February 23, 2024
Details:
The company intends to use the net proceeds for the advancement of its ongoing clinical development for SLN360 (zerlasiran) for the treatment of atherosclerotic cardiovascular disease.
Lead Product(s): Zerlasiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: 5AM Ventures
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 05, 2024
Details:
SLN360 (zerlasiran) is a siRNA (short interfering RNA) designed to lower the body’s production of lipoprotein(a), a key genetic risk factor for cardiovascular disease.
Lead Product(s): Zerlasiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2023
Details:
The collaboration aims to develop siRNAs (short interfering RNAs) leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to the first two targets in all territories except the China region.
Lead Product(s): siRNA
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: $1,316.0 million Upfront Cash: $16.0 million
Deal Type: Collaboration July 11, 2023
Details:
Under the agreement, Silence and AstraZeneca is focused on using Silence’s proprietary mRNAi GOLD™ platform to develop siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases.
Lead Product(s): siRNA Therapeutic
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $4,080.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration May 04, 2023
Details:
Silence will gain rights back to 2 undisclosed complement targets. SLN501, the C3 targeting program will remain under the agreement. Silence’s proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver.
Lead Product(s): siRNA-based Drug
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Mallinckrodt Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 28, 2023
Details:
SLN360 is a gene ‘silencing’ therapy, designed to temporarily blocks LPA, a gene that tells the body to make a specific protein that is only found in Lp(a). As the levels of Lp(a) are lowered, which lowers the risk of heart diseases, heart attacks and strokes.
Lead Product(s): SLN360
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
SLN360, is gene silencing therapy – one that is designed to temporarily block a specific gene’s message that would otherwise trigger an unwanted effect.In this case, it aims to ‘silence’ LPA, a gene that tells body to make a specific protein that is only found in Lp(a).
Lead Product(s): SLN360
Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
Silence and Hansoh entered a collaboration to develop siRNAs leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Under the terms of the agreement, Silence has exclusive rights to the rest two targets in all territories except the China region.
Lead Product(s): SLN-HAN-1
Therapeutic Area: Technology Product Name: SLN-HAN-1
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: $1,316.0 million Upfront Cash: $16.0 million
Deal Type: Collaboration April 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
